• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

'Exciting Era' Underway

Author(s):

Fred Wilson

San Francisco -- Patients with moderate to severe psoriasis can receive efalizumab (Anti-CD11a) continually with no increased toxicity for approximately one year, an ongoing open-label trial shows.

Related Videos
E. James Song is featured in this video series.
E. James Song is featured in this video series.
1 KOL is featured in this series.
2 KOLs are featured in this series.
E. James Song is featured in this video series.
E. James Song is featured in this video series.
Benjamin Lockshin, MD, FAAD, is featured in this series.
Related Content
Exploring the Effects of Masks on Skin Physiology
October 23rd 2024

Exploring the Effects of Masks on Skin Physiology

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
August 2nd 2024

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Clinical Pearls for Vitiligo and Pigmentation Complexities: Part 3
October 23rd 2024

Clinical Pearls for Vitiligo and Pigmentation Complexities: Part 3

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
July 1st 2024

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Which Tax Treatment Is Best for Your Dermatology Practice?
October 23rd 2024

Which Tax Treatment Is Best for Your Dermatology Practice?

Facing Challenges in Pediatric Plaque Psoriasis
October 23rd 2024

Facing Challenges in Pediatric Plaque Psoriasis

© 2024 MJH Life Sciences

All rights reserved.